Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Royal DSM N.V.    DSM   NL0000009827

ROYAL DSM N.V.

(DSM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Royal DSM : DSM boosts maternal and infant nutrition portfolio with new plant-based high potency DHA oil

share with twitter share with LinkedIn share with facebook
05/11/2020 | 04:54am EDT

Parsippany, NJ (US), 11 May 2020 04:45 EST

Royal DSM, a purpose-led, global science-based company active in Nutrition, Health and Sustainable Living, announces the launch of its new, high-quality life'sDHA® SF55-O200DS oil for maternal and early life nutrition solutions. Offering a higher potency, this ingredient contains a minimum of 550 mg/g natural triglyceride DHA (docosahexaenoic acid), allowing manufacturers to achieve equivalent dosages of DHA in smaller product formats and meet the latest maternal nutrition trend for convenient capsule and tablet sizes1.

This latest addition to DSM's broad nutritional portfolio is the only 550 mg/g natural triglyceride DHA intended for use in maternal nutrition and is aimed for women who are planning to conceive, are pregnant, breastfeeding or non-breastfeeding post-natal mothers. Produced from Schizochytrium algae, life'sDHA SF55-O200DS offers a sustainable plant-based alternative to fish oil and is made with ingredients of conventional (non-GM) origin. A trusted source of contaminant-free, kosher and halal omega-3, life'sDHA SF55-O200DS supports infant health and development and can be consumed in a single, convenient dose.

'Convenience, quality and safety are key drivers of consumer purchasing in the maternal and early life nutrition markets, with mothers and expectant moms looking for easy-to-swallow dietary supplements and safe infant nutrition products made with trusted, science-backed ingredients, comments Brent MacDonald, Director Global Marketing & Business Development, Nutritional Lipids at DSM. 'We carefully formulated life'sDHA SF55-O200DS to help manufacturers develop high-quality, reliable DHA solutions that will give pregnant women and moms peace of mind and that will shape healthier futures worldwide.'

Disclaimer

Koninklijke DSM NV published this content on 11 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2020 08:53:01 UTC

share with twitter share with LinkedIn share with facebook
Latest news on ROYAL DSM N.V.
07/01ROYAL DSM N : Appoints Zhou Tao (Joe) as DSM China President
PU
06/30ROYAL DSM N : DSM halves the carbon footprint of Akulon® PA6
PU
06/24ROYAL DSM N : DSM takes over part of Clariant's 3D printing business portfolio t..
PU
06/17ROYAL DSM N : DSM issues €1 billion long-term bonds to finance acquisition of Er..
PU
06/12ROYAL DSM N : DSM finalizes share repurchase to cover share plans and stock divi..
PU
06/12ROYAL DSM N : DSM to add world-leading animal nutrition and health specialty bus..
PU
06/02ROYAL DSM N : DSM introduces Again™, commercial carpet designed for circul..
PU
05/19ROYAL DSM N : Open collaborative platform UNITE4COVID launched to accelerate Cov..
PU
05/13ROYAL DSM : Presentation to AGM
PU
05/12ROYAL DSM : Ex-dividend day for final dividend (optional)
FA
More news
Financials
Sales 2020 8 884 M 10 032 M 10 032 M
Net income 2020 757 M 855 M 855 M
Net Debt 2020 2 151 M 2 429 M 2 429 M
P/E ratio 2020 28,9x
Yield 2020 1,97%
Capitalization 21 442 M 24 248 M 24 213 M
EV / Sales 2019
EV / Sales 2020 2,66x
Nbr of Employees 22 174
Free-Float 94,7%
Chart ROYAL DSM N.V.
Duration : Period :
Royal DSM N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL DSM N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 117,59 €
Last Close Price 126,30 €
Spread / Highest target 15,8%
Spread / Average Target -6,89%
Spread / Lowest Target -42,2%
EPS Revisions
Managers
NameTitle
Dimitri de Vreeze Co-Chief Executive Officer & COO
Géraldine Matchett Co-Chief Executive Officer & CFO
Robert John Routs Chairman-Supervisory Board
Pauline F. M. van der Meer Mohr Deputy Chairman
Eileen A. Kennedy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
ROYAL DSM N.V.8.79%24 248
BASF SE-24.56%52 114
SHIN-ETSU CHEMICAL CO., LTD.3.86%48 253
DUPONT DE NEMOURS, INC.-14.94%39 420
GROUPE BRUXELLES LAMBERT-17.82%13 250
FMC CORPORATION1.32%13 092